Get the Stockscreener App
11.21
0.88%
-0.10
After Hours:
11.21
Pliant Therapeutics Inc stock is traded at $11.21, with a volume of 238.79K.
It is down -0.88% in the last 24 hours and down -15.65% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$11.31
Open:
$11.25
24h Volume:
238.79K
Relative Volume:
0.50
Market Cap:
$680.06M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-4.0912
EPS:
-2.74
Net Cash Flow:
$-139.79M
1W Performance:
-0.97%
1M Performance:
-15.65%
6M Performance:
-24.77%
1Y Performance:
-35.35%
1-Day Range:
$10.96
$11.43
1-Week Range:
$10.96
$11.65
52-Week Range:
$10.29
$19.62
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World
Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa
Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com UK
Investing in Pliant Therapeutics Inc (PLRX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Pliant Therapeutics Inc (PLRX) receives an Outperform rating from Leerink Partners - Knox Daily
Pharma stock to buy now for an upside of 20%; Are you holding it? - Trade Brains
5,372 Shares in Piper Sandler Companies (NYSE:PIPR) Purchased by Intech Investment Management LLC - MarketBeat
Berkley W R Corp Cuts Stock Position in Plum Acquisition Corp. I (NASDAQ:PLMI) - Defense World
Great Point Partners LLC Raises Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Priority Technology (NASDAQ:PRTH) Reaches New 1-Year High After Analyst Upgrade - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
First Light Asset Management LLC Sells 133,780 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Palfinger (OTCMKTS:PLFRY) Trading Down 2% - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Down 5.4% - MarketBeat
Pulse Biosciences Inc [PLSE] Investment Appeal on the Rise - Knox Daily
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Rhumbline Advisers Raises Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Inspire Investing LLC Sells 8,725 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to "Sell" - MarketBeat
Piper Sandler Companies (NYSE:PIPR) Shares Acquired by Commonwealth Equity Services LLC - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 2.7% - MarketBeat
Piper Sandler Companies (NYSE:PIPR) Rating Reiterated by JMP Securities - Defense World
JMP Securities Reaffirms “Market Perform” Rating for Piper Sandler Companies (NYSE:PIPR) - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 2.7% - Defense World
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Piper Sandler maintains Overweight rating on Pliant Therapeutics shares By Investing.com - Investing.com Canada
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - MarketBeat
What is the investor’s view on Pliant Therapeutics Inc (PLRX)? - US Post News
Statera Biopharma (NASDAQ:STAB) & Pliant Therapeutics (NASDAQ:PLRX) Financial Analysis - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Purchased by Bank of New York Mellon Corp - Defense World
PLRX’s latest rating updates from top analysts. - Knox Daily
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Ratio Review: Analyzing Pliant Therapeutics Inc (PLRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
This trade activity should not be overlooked: Pliant Therapeutics Inc (PLRX) - SETE News
HC Wainwright Reiterates Buy Rating for Pliant Therapeutics (NASDAQ:PLRX) - Defense World
Quest Partners LLC Has $346,000 Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Target Price at $40.57 - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Reiterates Buy Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt? - Simply Wall St
Rice Hall James & Associates LLC Takes $1.37 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World
Brokers Set Expectations for Pliant Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics: Good Data, But Will Need Watching (NASDAQ:PLRX) - Seeking Alpha
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 4.2% - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Forecasted to Post Q1 2025 Earnings of ($0.97) Per Share - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):